CHICAGO – Newer drugs are substantially improving the chances of survival for some people with hard-to-treat forms of lung, breast and prostate cancer, doctors reported at the world’s largest cancer conference. Companies that make the drugs sponsored the studies, and some study leaders have financial ties. Standard treatment is drugs that block the male hormone testosterone, which helps these cancers grow, plus chemotherapy or a newer drug called Zytiga. The other study involved 1,052 men who were given hormone therapy with or without the Janssen drug Erleada. The other three drugs are pills that cost more than $10,000 a month and are taken indefinitely.

Source: Philippine Daily Inquirer June 02, 2019 22:41 UTC